B. Riley Financial Reaffirms “Buy” Rating for Novavax (NASDAQ:NVAX)

Novavax (NASDAQ:NVAX)‘s stock had its “buy” rating reissued by stock analysts at B. Riley Financial in a research report issued on Friday, Benzinga reports. They presently have a $16.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $18.00. B. Riley Financial‘s price objective would indicate a potential upside of 51.34% from the stock’s current price.

Several other equities research analysts also recently issued reports on the company. Citigroup restated a “sell” rating and set a $8.00 price objective (up from $7.00) on shares of Novavax in a report on Thursday, October 15th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Novavax in a research report on Monday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Novavax in a research note on Tuesday, October 27th. Zacks Research downgraded shares of Novavax from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen raised shares of Novavax from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Novavax presently has an average rating of “Hold” and a consensus price target of $12.33.

Novavax Stock Performance

Shares of NASDAQ NVAX traded up $0.79 during midday trading on Friday, reaching $10.57. 1,428,203 shares of the company’s stock were exchanged, compared to its average volume of 5,184,553. Novavax has a 52-week low of $6.20 and a 52-week high of $13.39. The stock has a market capitalization of $1.74 billion, a PE ratio of -6.91 and a beta of 2.65. The business’s fifty day moving average price is $10.52 and its two-hundred day moving average price is $9.33.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.16. The business had revenue of $68.30 million for the quarter, compared to analysts’ expectations of $50.42 million. Novavax had a negative return on equity of 14.82% and a negative net margin of 59.87%. The company’s revenue was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.25) earnings per share. Analysts predict that Novavax will post -0.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Novavax

Hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its holdings in Novavax by 4.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 27,820 shares of the biopharmaceutical company’s stock valued at $295,000 after buying an additional 1,207 shares during the last quarter. KBC Group NV boosted its holdings in shares of Novavax by 34.9% in the 1st quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 1,229 shares during the period. Allworth Financial LP grew its position in shares of Novavax by 292.5% during the 2nd quarter. Allworth Financial LP now owns 4,353 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 3,244 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Novavax by 15.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 30,096 shares of the biopharmaceutical company’s stock worth $326,000 after acquiring an additional 3,926 shares during the period. Finally, Abel Hall LLC raised its stake in Novavax by 30.7% during the first quarter. Abel Hall LLC now owns 18,050 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 4,241 shares during the period. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax News Summary

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax raised its 2026 adjusted revenue outlook by $145 million to a $385 million–$415 million range, with a midpoint of $400 million, slightly above analyst expectations. A $125 million milestone from Sanofi contributed to the increase. Reuters report on Novavax’s raised forecast
• Positive Sentiment: Q3 results beat estimates: revenue was $68.3 million versus expectations of $50.4 million, while the loss of $0.19 per share was narrower than the expected $0.35 loss. Novavax also said operating expenses fell 41% year over year. Q3 earnings-call highlights
• Positive Sentiment: The company expects its cash runway to extend into 2029, easing near-term funding concerns. Sanofi also intends to begin a U.S. Phase 3 trial of its flu-COVID combination vaccine with Novavax in 2027. Novavax Q3 results and operational update
• Negative Sentiment: Despite beating estimates, Q3 revenue declined 3% year over year, and the improved full-year outlook relies partly on the Sanofi milestone, which may not represent recurring product sales. Q3 sales and guidance analysis
• Negative Sentiment: Reports that Novavax pushed its profitability target to 2029 may weigh on sentiment, highlighting that stronger revenue and cost control have not yet translated into near-term profitability. Report on Novavax’s profitability target

About Novavax

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.